# An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma

> **NCT01351571** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 5 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01351571
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351571, "An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01351571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*